



Consommation
et Corporations Canada

Consumer and
Corporate Affairs Canada

Bureau des brevets

Patent Office

Ottawa, Canada
K1A 0C9

(11) (C) **1,305,921**

(21) 557,096

(22) 1988/01/21

(45) 1992/08/04

(52) 167-44

(51) INTL.CL.⁵ G01N-33/543; G01N-33/569

(19) (CA) **CANADIAN PATENT** (12)

(54) Diffraction Immunoassay and Reagents

(72) Gustafson, Eric K. , U.S.A.
Trebino, Rick , U.S.A.
Lee, John , U.S.A.
Yuh-geng, Tsay , U.S.A.
Calenoff, Emanuel , U.S.A.

(73) Adeza Biomedical Corporation , U.S.A.

(30) (US) U.S.A. 9,177 1987/01/30
(US) U.S.A. 30,327 1987/03/26
(US) U.S.A. 34,876 1987/04/06

(57) 20 Claims

5

FIELD OF THE INVENTION

This invention relates to an improved immunoassay method and reagents therefor. In particular this invention relates to an
10 light diffraction immunoassay method and reagents which provide enhanced sensitivity.

BACKGROUND OF THE INVENTION

Many solid-phase immunoassays involve surface illumination and
15 consequent light emissions from molecules attached to the surface. Generally, these emissions travel in all directions. Either these divergent emissions must be collected with expensive and awkward light collection optics to achieve sensitivity or the inherent inefficiencies and consequent low signal to light level ratios must
20 be accepted.

Diffraction gratings cause light to be diffracted into specific angles versus being scattered in all directions. This constructive light interference property of a grating allows efficient collection of light. Diffraction gratings have been used for
25 dispersing light into its spectral components. The original gratings were prepared by ruling a number of straight, parallel grooves in a surface. Incident light is diffracted by each of the surfaces and is principally directed in directions in which light from each groove interferes constructively with light scattered by
30 the other grooves.

Many immunoassay systems have been developed using different physically measurable properties of reagents to provide a measurement of an analyte concentration in a sample.



1305921

-3-

Radioimmunoassay (RIA), immunofluorescence, chemiluminescence, enzyme immunoassays (EIA), free radical immunoassays (FRAT), light scattering nephelometry, transistor bridge probes, indium reflective surfaces, and ultrasonic probes have been

- 5 applied. These systems use the highly selective reaction between a primary binding reagent material such as an antibody or antigen and an analyte selectively binding therewith.

DESCRIPTION OF THE PRIOR ART

- 10 U.S. Patent 4,647,544 corresponding to European Patent Application 85304496.4 published January 8, 1986 describes a light diffraction system and method, and biogratings therefor.

- Disclosed methods for forming the biogratings comprise
15 forming a coating of an active antibody on a flat surface such as a glass or plastic surface. In one method disclosed, the selective destruction of antibody molecules to form the stripe-like regions is accomplished with an intense UV source such as a mercury lamp together with a shadow mask placed near or in contact with the
20 coated surface. Binding of analytes with the stripes of active antibody yields a light-diffracting grating. In sandwich immunoassay and competition immunoassay applications of this technology, a labeled reagent ligand can be used to enhance the mass of the bound material.

- 25 This invention provides an improvement in the biograting and the method of the manufacture thereof which reduces non-specific binding and increased sensitivity, and permits the detection and measurement of smaller analyte molecules and lower concentrations of analyte molecules with or without use of a labeled reagent
30 ligand.

An attempt by others to develop an optical probe comprising a metal covered diffraction grating coated with a monoclonal antibody specific for a virus, bacterium or other desired antigen has been

1305921

-4-

described by Moffatt, A. *Genetic Engineering News*. p 18, October, 1986. The shift in wavelength of reflected light is apparently determined and correlated to a concentration in analyte. Moffatt says the manufacture of the grating in commercial quantities has not been achieved because he lacks a suitable method
5 for mass production of quality gratings.

A reflectance method for quantification of immunological reactions on polished crystalline silicon wafer surfaces has been described by Arwin, H. et al, *Analytical Biochemistry*.
10 154:106-112 (1985). Indium surface reflection methods are described by Giaever in U.S. Patents 3,853,467, 3,926,564, 3,960,488, 3,960,489, 3,960,490, 3,975,238, 3,979,184, 3,979,509, 4,011,308, 4,018,886, 4,054,646, 4,115,535, 4,172,827 and 4,181,501. Liquid layer thicknesses can be monitored by a
15 reflectance method described in U.S. Patent 3,960,451.

Biosensors such as field effect transistors probes and their use in assays are described by Pace, S., *Medical Instrumentation*. 19:168-172 (1985). Polysilicon surfaces are included among the possible biosensor surfaces to which primary binding reagents can
20 be attached.

Photoresists and laser light have been used to make holographic gratings. The coarseness of the photographic medium restricts the groove spacing. Use of photoresist masks in the production of precisely configured shapes and lines in semiconductor material is
25 widely used in the production of semiconductor devices. The masks can be placed or very near the surface to be exposed in one application referenced in U.S. Patent 4,647,544. In this approach, the best definition is obtained by pressing the mask against the surface to be exposed with high pressure to minimize light
30 reflection at the edges of the masking elements. An alternate approach requires the use of a focusing lens, where the mask is positioned to form a shadow on the surface to be exposed.

1305921

-5-

SUMMARY OF THE INVENTION

This invention involves a discovery of supporting surfaces for the biogrid which provide greatly reduced non-specific binding and of grid manufacturing techniques.

- 5 One aspect of the process of this invention is an improvement in the process for manufacturing a biograting for use in a light diffraction immunoassay comprising adhering a uniform layer of binding reagent on a smooth, solid surface and exposing the surface to UV radiation through a shadow mask with diffraction grating
- 10 lines to selectively deactivate the binding reagent leaving a biological diffraction grating design of lines of active binding reagent, the improvement comprising applying the binding reagent to a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a
- 15 biological diffraction grating design of lines of active binding reagent. Preferably, the insoluble surface is polysilicon; the binding reagent is selected from the group consisting of antibody, antigen, hapten, protein A, lectin, biotin and avidin; and the biogrid is formed by casting a precise focused shadow on the
- 20 binding reagent layer without physically contacting the binding reagent layer with the shadow mask.

- Another aspect of the process of this invention is an improvement in the process for manufacturing a biograting for use in a light diffraction immunoassay comprising adhering a uniform
- 25 layer of binding reagent on a smooth, solid surface and exposing the surface to UV radiation through a shadow mask with diffraction grating lines to selectively deactivate the binding reagent to leave a biological diffraction grating design of lines of active binding reagent, the improvement comprising casting a precise
- 30 focused shadow on the binding reagent layer without physically contacting the binding reagent layer with the shadow mask. Preferably, the binding reagent is selected from the group consisting of antibody, antigen, hapten, protein A, lectin, biotin

1305921

-6-

and avidin and the binding reagent is applied to a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces.

5 A biograting of this invention for use in a light diffraction immunoassay comprises a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent.

10 Another biograting of this invention for use in a light diffraction immunoassay comprises a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent which is the product of the process of adhering a uniform layer of binding reagent on a smooth, solid
15 surface and exposing the surface to UV radiation through a shadow mask with diffraction grating lines to selectively deactivate the binding reagent to leave a biological diffraction grating design of lines of active binding reagent, wherein a precise focused shadow is cast on the binding reagent layer without physically contacting
20 the binding reagent layer with the shadow mask.

With the improved biograting of this invention, the binding reagent is preferably chosen to bind selectively the organic analyte such as a microbe or fragment of a bacteria, virus, Mycoplasmatales, spore, parasite, yeast, enzyme, carbohydrate,
25 antigenic protein such as an immunoglobulin, or organic compounds and substances having lower molecular weights. Because of the improved sensitivity with this invention, no enhancement of signal output with a labeled secondary reagent is required.

30 The diffraction binding assay method of this invention for determining the presence or quantity of an analyte in an aqueous sample comprises contacting a diffraction binding assay surface with the sample for a time sufficient to permit conjugation of binding reagent and analyte, the diffraction binding assay surface

1305921

-7-

being selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a light disturbing design of substantially non-light disturbing binding reagent thereon, the binding reagent being selected to bind
5 selectively with the analyte; separating the surface from the sample; and illuminating the diffraction binding assay surface with light from a light source, and determining the light diffracted by the diffraction binding assay surface. The analyte can be a microbe or fragment thereof including a bacteria, virus,
10 Mycoplasmatales, spore, parasite, yeast, or fragment thereof. Alternatively, the analyte can be an organic substance having a molecular weight within the range of from 10,000 to 2,000,000 daltons such as an enzyme, enzyme inhibitor, enzyme substrate, immunoglobulin, hormone, drug, drug metabolite, receptor, tumor
15 associated marker, or carbohydrate.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic of incident and diffracted light designs in the method of this invention.

20 Fig. 2 is a schematic view of a stationary platform embodiment of the diffraction immunoassay apparatus of this invention.

Fig. 3 is a schematic view of a rotating platform embodiment of the diffraction immunoassay apparatus of this invention.

25 Fig. 4 is a cross-sectional view of a dipstick having mounted thereon, a plurality of insoluble supports with diffraction grating designs of reagents on the surfaces thereof.

Fig. 5 is a fragmentary, magnified cross-sectional view of an insoluble support having primary binding reagent on the surface thereon in a diffraction grating design.

30 Fig. 6 is a schematic representation of the process for manufacturing an insoluble support with the diffraction grating design of Fig. 5.

Detailed Description of the Invention

This invention is an improvement of an immunoassay applying light diffraction. By forming a grating of binding reagent-analyte complexes on the surface of an insoluble support, the incident
5 light can be diffracted into a discrete series of angles, and the light can be detected and measured with a high efficiency. The angle of diffraction is a function of the grating line spacing and the wavelength of the incident light.

The term "binding reagent" is used herein to designate one
10 member of a binding pair of compounds or materials which selectively bind to form a conjugate. The term "primary binding reagent" is used herein to designate the non-light disturbing binding reagent which is applied to the insoluble surface to form a diffraction grating design of non-light disturbing material. The
15 binding reagent can be a member of the well-known antibody-antigen or antibody-hapten pairs wherein the antibody binds selectively with the respective antigen or hapten, or combinations where the antibody is replaced with an Fa, Fb, Fab, F(ab')₂ fragment or hybrid antibody. The binding reagent can also be a member of other
20 types of binding pairs such as biotin-avidin; lectin-sugar; IgG antibody Fc portion with protein A; enzyme-enzyme substrate; enzyme-enzyme inhibitor; protein-protein receptor; chelating agent-ligand; and the like. Also included are specific binding pairs wherein a mercapto group binds specifically with a dithio or
25 disulfide group (-SH - -S-S-) or with a N-substituted-2,4-diketo-3-pyrroline group, and other molecules with functional groups that will bind each other specifically. In general, the binding reagent is selected to bind specifically or selectively with the analyte, the material for which a sample is assayed. A non-light disturbing
30 layer or coating of binding reagent is applied to an insoluble surface and is transformed into a diffraction grating design of non-light disturbing material for use in the method of this invention.

1305921

-9-

The term "anti-microbe antibody", as used herein, is defined to be an antibody which specifically binds with a surface epitope of a microbe analyte and will bind it to the insoluble support. The term "microbe" as used herein is defined to include bacteria, parasites, virus, Mycoplasmatales, spores, molds, yeasts, other
5 living organisms of a microscopic or sub-microscopic size, and fragments thereof.

The term "binding assay", is used herein to designate an assay using any binding reaction between a binding reagent and the other
10 member of the binding pair which is selectively bindable therewith.

The term "light disturbing", as used herein, is defined to include all ways in which light is affected including light absorbing, reflecting, scattering, refracting and phase changing.

The term "diffraction grating", as used herein, is defined to
15 include reflection amplitude gratings which are formed in one or more immunological steps. In one step gratings, the diffraction grating is formed directly by the conjugation of the non-light disturbing reagent on the insoluble surface with a light disturbing analyte. In multistep gratings, the conjugation product of the
20 non-light disturbing reagent on the insoluble surface with the analyte is non-light disturbing. By conjugation of the analyte with a light disturbing material in one or more further conjugations, a multistep grating is formed. Types of single and multistep gratings formed in the process of this invention include
25 reflection amplitude gratings, transmission amplitude gratings, reflection phase gratings, and transmission phase gratings. In reflection amplitude gratings in one or more steps, light is reflected from the grating, and the amplitude of the reflected light is modulated by the spatially variable reflection of the
30 grating. In transmission amplitude gratings in one or more steps, light is transmitted through the grating, and the amplitude of the transmitted light is modulated by the spatially variable transmission of the grating. In the reflection phase grating in

1305921

-10-

one or more steps, the light is reflected from the grating, and the phase of the reflected light is modulated by the spatially variable refractive index of the grating. In the transmission phase gratings in one or more steps, light is transmitted through the
5 grating, and the phase of the transmitted light is modulated by the spatially variable refractive index of the grating. In the method of this invention, the diffraction grating may function as one or more of these types of gratings concurrently, and all of these grating types are included within the diffraction gratings of this
10 invention.

Fig. 1 is a schematic of incident and diffracted light designs produced by incident light impinging on the diffraction grating in the method of this invention. The incident light 2 impinges on a diffraction grating 4 on the surface of the insoluble support 6.
15 Reflected light 8 ($m = 0$) is reflected at angle B^0 which is equal to angle A, the angle of incidence, measured with respect to the normal 10 to the grating surface 4. Diffracted light is diffracted by the grating 4 in a series of angles. The relationship between the angle of incident and the angle of diffraction is provided by
20 the basic grating equation:

$$m\lambda = d(\sin A - \sin B)$$

wherein m is the spectral order of wavelength λ , d the groove spacing, and A and B are the angles of incidence and diffraction, respectively, with respect to the normal to the grating surface.
25 The first order diffractions 12 ($m = -1$) and 14 ($m = 1$) have angles B^{-1} and B^{+1} . The second order diffractions 16 ($m = -2$) and 18 ($m = 2$) have angles B^{-2} and B^{+2} with respect to normal 10. Light is also diffracted at higher orders. The first and second order diffractions are shown by way of example, not as a
30 limitation, and all diffractions having a significant intensity can be used in the method of this invention.

Fig. 2 is a schematic view of a stationary platform embodiment of the diffraction immunoassay apparatus of this invention. The

1305921

-11-

light beam 19 from the light source 20 passes through chopper 22 and beam splitter 24. The light passing the splitter passes through collimator 26 and impinges on the diffraction grating 28 mounted on the stationary support 29.

5 A diffracted beam leaving the grating surface 28 is represented by single line 32 having an angle B with respect to the normal 30. The reflected beam is not shown. The light is collected with lens 34, is passed through an aperture 36 and impinges on the light sensor 38, generating an electrical signal which is carried to the
10 conventional lock-in amplifier and recorder system 40 by cable 42. A split beam 43 of light diverted by the splitter 24 from the primary beam 19 is directed against another light detector 44. The electrical signal from the light detector 44 is fed by cable 46 to the lock-in amplifier 40 as a reference signal for compensating
15 slow drift errors originating from the light source. Cable 48 provides a reference signal from the chopper 22 to the lock-in amplifier 40 for the lock-in function. This function synchronizes the chopper speed (the light bundles passing the chopper) with the operation (opening) of the amplifier filter, thus reducing ambient
20 light noise. The components of the system and their individual functions including the light source, splitter, chopper, collimator, lens, light detectors and lock-in amplifier are conventional and well-known in the art.

The diffraction measuring apparatus schematically represented
25 in Fig. 2 can be constructed to change the angles A and B. The light source 20, chopper 22, beam splitter 24 and collimator 26 can be mounted on an arm which mounted to rotate in a vertical plane around the diffraction grating 28 to a preferred angle A. Angle A is preferably within the range of from 10 to 80° and optimally
30 within the range of from 20 to 70°. Even more importantly, the lens 34, aperture 36 and light detector 38 can be mounted on an arm for rotation in a vertical place around the diffraction grating 28 through angles B which place the lens and aperture in the paths of

1305921

-12-

the reflected light beam 8 and the diffracted light beams represented by 12, 14, 16 and 18 in Fig. 1. In this manner, a single detector system can be rotated to detect and measure the reflected light and all desired orders of the diffracted light.

5 Fig. 3 is a schematic view of a rotating platform embodiment of the diffraction immunoassay apparatus of this invention. The light beam 50 from the light source 52 passes through the beam splitter 54. The light passing the splitter passes through collimator 56 and impinges on the diffraction grating 58 mounted on the rotating
10 support 60.

The diffracted light beam 62 leaving the grating surface 58 has an angle B with respect to the normal 64 to the grating surface. The light is collected with lens 66, is passed through an aperture 68 and impinges on the light sensor 70, generating an electrical
15 signal which is carried to the conventional lock-in amplifier and recorder system 72 by cable 74. A split beam 76 of light diverted by the splitter 54 from the primary beam 50 is directed against another light detector 78. The electrical signal from the light detector 78 is fed by cable 80 to the lock-in amplifier 72 as a
20 reference signal for compensating slow drift errors originating from the light source 52. Cable 81 provides a signal from the platform rotating system 82 to the lock-in amplifier 72 for the lock-in function. This function synchronizes the platform speed (the periodic alignment of the grating and light diffraction
25 designs therefrom with the lens 66 and aperture 68) with the operation (opening) of the amplifier filter, thus reducing ambient light noise. The components of the system and their individual functions including the light source, splitter, light detectors and lock-in amplifier are conventional and well-known in the art.

30 The diffraction measuring apparatus schematically represented in Fig. 3 can also be constructed to change the angles A and B. The light source 52, beam splitter 54 and collimator 56 can be mounted on an arm which mounted to rotate in a vertical plane

1305921

-13-

around the diffraction grating 58 to a preferred angle A. Angle A is preferably within the range of from 10 to 80° and optimally within the range of from 20 to 70°. Even more importantly, the lens 66, aperture 68 and light detector 70 can be mounted on an arm
5 for rotation in a vertical plane around the diffraction grating 58 through angles B which place the lens and aperture in the paths of the reflected light beam 8 and the diffracted light beams represented by 12, 14, 16 and 18 in Fig. 1. As in the embodiment shown in Fig. 2, a single detector system can be rotated to detect
10 and measure the reflected light and all desired orders of the diffracted light.

Alternatively, a stationary array of lens, aperture and detector sets can be positioned at preset angles to coincide with the paths of the reflected and diffracted light for both of the
15 systems of Fig. 2 and Fig. 3. For most simple embodiments of these systems, a stationary lens, aperture and light detector set can be positioned in the path of a first, second or third order diffracted beam. Other suitable combinations of stationary and movable arrays of detectors will be apparent to a person skilled in the art, and
20 all of these permutations and combinations are intended to be within this invention.

The light sources 20 (Fig. 2) and 52 (Fig. 3) are preferably narrow band light sources which can include filtered light from an incandescent light bulb or sun light. The most preferred light is
25 intense narrow band light which is collimated and optimally polarized. The narrow band frequency can be within the range of from 200 to 1400 nm having a band width within the range of from 10 to 80 nm and is optimally within the range of from 400 to 800 nm having a band width of from 10 to 20 nm or lower. The output power
30 or output energy level of the light source can be 0.1 milliwatts and higher, the higher the power level, the better the results.

The optimum light sources are monochromatic light sources such as lasers. Optimum monochromatic light sources are lasers such as

1305921

-14-

helium-neon laser, diode laser, diode pumped solid state laser, argon ion laser, helium-cadmium laser, YAG, harmonics of YAG, ruby, excimer and tunable dye lasers. The light can be polarized or not polarized. Linear polarization in the plane of incidence is
5 optimum.

The light chopper 22 (Fig. 2) can be any conventional light chopper. It can comprise a rotating plate defining evenly radially spaced windows at a constant distance from the axis of rotation of the plate.

10 A beam expander can be optionally provided in the light paths 19 and 50 to increase the cross-sectional area of the beams and increase the surface area of the diffraction grating interacting with the light to increase sensitivity. Preferred beam expanders are conventional lens or prism systems which convert an incident
15 collimated light beam into an emitted collimated beam of larger size.

The collecting lenses 34 (Fig. 2) and 66 (Fig. 3) collect each of the diffracted light beams and concentrate or focus them into smaller beams having a cross-sectional area less than the surface
20 area of the light detectors 38 and 70. Any conventional lens system can be used which provides the desired reduction or focusing.

The light detectors 38 and 70 can be any devices which can quantitatively convert incident light intensity to voltage or
25 current in a proportional manner. Conventional light detectors such as photomultiplier tubes or semiconductor-based detectors such as silicon, germanium or gallium arsenide can be used.

The amplifier and recorder systems 40 and 72 can be any conventional system which is customarily used for amplifying an
30 input signal from a light detector and recording a value functionally related thereto. A simple system can comprise a bias supply and an oscilloscope adjusted to show the amplitude of the output signal of each light detector 38 and 70. For more

1305921

-15-

sensitivity, a lock-in amplifier which uses a reference signal from the chopper (Fig. 2) or rotating mount (Fig. 3) to perform the functions described above. These amplifiers are standard, commercially available systems fully within the existing skill of the art and are not a part of this invention.

The platform 6 (Fig. 1) is designed to support a diffraction grating in a precise position of alignment with the incident light beam 2. The configuration of the platform 6 is determined by the shape of the diffraction surface support and whether more than one diffraction surface is mounted on a diffraction surface support.

Fig. 4 is a cross-sectional view of a dipstick having mounted thereon, a plurality of insoluble supports with non-light disturbing diffraction grating designs of reagents on the surfaces thereof. The dipstick body 130 has a plurality of insoluble support surfaces 134 having a diffraction grating design of binding reagent coated thereon. The materials from which the dipstick is made should be non-binding to minimize non-specific binding during the immunoassay procedure. Suitable dipstick surface materials include polyolefins such as polyethylene and polypropylene, hydrophilic polysilicon and polysiloxane polymers, and the like. Also suitable are polymers which have been treated to render the surfaces non-binding to proteinaceous materials.

The support for the diffraction grating supports can be any articles upon which the diffraction grating support surface can be mounted. The description of dipsticks are provided by way of example, and not as a limitation. Other articles such as microwells, plates, cavities and the like can be used. For many applications, dipsticks are a preferred embodiment.

Fig. 5 shows one embodiment of a diffraction grating element of this invention. Fig. 5 is a fragmentary, magnified cross-sectional view of an insoluble support having primary binding reagent on the smooth surface thereof in a non-light disturbing diffraction grating design. The insoluble support 140 of this embodiment has a

1305921

-16-

- smooth upper surface 142 upon which the diffraction grid design or pattern is coated. The diffraction grating design comprises a plurality of lines 144 of non-light disturbing active primary binding reagent thinly coated and adhering to the upper
- 5 surface 142. The lines 144 are separated by lines 146 of deactivated primary binding reagent, for example, primary binding reagent which has been deactivated by exposure to ultraviolet (UV) radiation, other deactivating radiation or other deactivation energy.
- 10 The grating can have any number of lines 144 which will provide a diffraction design with the incident light wavelength. The preferred density of lines 144 are from 250 to 10,000 lines per cm for polarized monochromatic light having a wavelength of from 600 to 800 nm. The optimum density of lines 144 is from 1250 to 2500
- 15 lines per cm for polarized monochromatic light having a wavelength of from 600 to 850 nm. The lines 144 have a preferred width (a) of from 0.5 to 20 microns and an optimum width of from 2 to 8 microns. The spacing "d" between the center of adjacent lines 144 is preferably from 0.5 to 20 microns and optimally from 1 to 12
- 20 microns. The lines 144 and 146 can be of any desired thickness, depending upon the nature of the primary binding reagent. For antibody and antigen coatings adhered to the surface 142 by adsorption or other bonding procedures, the coating thickness is preferably a thin coating, yielding a layer which is non-light
- 25 disturbing. Prior to the conjugation of the coating 144 with a non-light disturbing substance, the grating is non-diffracting, that is, no diffraction occurs when it is exposed to light. When the coating 144 is conjugated with a light disturbing substance, the grating becomes a diffracting grating. The proportion of light
- 30 diffracted is a function of the concentration or quantity of light disturbing materials conjugated with the coating 144, and this value can be used to verify the presence of analyte and to quantify the concentration of analyte present in a sample.

1305921

-17-

The smooth upper surface 142 can be any material to which a primary binding reagent can be adhered by physical or chemical bonding and which will not interfere with the reactions which are used to determine the presence and extent of the conjugating
5 reaction. Organic and inorganic polymers, both natural and synthetic, can be used as the insoluble support. Examples of suitable polymers include polyethylene, polypropylene, polybutylene, poly(4-methylbutylene), butyl rubber, silastic polymers, polyesters, polyamides, cellulose and cellulose
10 derivatives (such as cellulose acetate, nitrocellulose and the like), acrylates, methacrylates, vinyl polymers (such as polyvinyl acetate, polyvinyl chloride, polyvinylidene chloride, polyvinyl fluoride, and the like), polystyrene and styrene graft copolymers, rayon, nylon, polyvinylbutyrate, polyformaldehyde, etc. Other
15 materials which can be used as the insoluble support can be silicon wafers, glass, insoluble protein coatings on a smooth insoluble surface, metals, metalloids, metal oxides, magnetic materials, materials used in semiconductor devices, cermets and the like.

The preferred diagnostic supports of this invention have a
20 superior adsorptive quality for physical, non-covalent binding of proteins, including primary binding reagents and proteinaceous materials applied to reduce the non-specific binding of the ultimate coating. We have discovered that materials previously used in the manufacture of semiconductor devices have superior
25 qualities in this respect. Suitable materials include polished single crystalline aluminum, silicon, epitaxial silicon coatings, silicon nitride coatings, silicon dioxide coatings, and polysilicon coatings. The optimum surfaces have a polysilicon coating. The most optimum supports 140 are single crystal silicon wafers having
30 a polysilicon coating on the outer polished surface thereof.

The polysilicon surface is preferably a thin film of polysilicon deposited on a suitable surface, preferably a highly polished surface such as a single crystalline silicon wafer.

1305921

-18-

Silicon's lattice structure provides a highly uniform surface with superior properties as an immunoreagent support. Polysilicon films were developed in the semiconductor industry as valuable dielectric materials. They are used as gate electrodes in MOS devices, for
5 high value resistors, diffusion sources to form shallow junctions, conductors and to ensure ohmic contact to crystalline silicon. The term "polysilicon" as used herein is synonymous with the term "polycrystalline silicon". These films are conventionally prepared by chemical vapor deposition techniques. These films and method
10 for their preparation are described by A.C. Adams in "Dielectric and Polysilicon Film Deposition", VLSI TECHNOLOGY, (S.M.Sze ed.) New York: McGraw-Hill, pp 93-129 (1983) and the citations therein.

The surface upon which the polysilicon is coated can be any
15 material which is stable at polysilicon deposition temperatures. It can be prepared by pyrolyzing silane at 600 to 650 C in a partial vacuum. Lower pyrolysis temperatures are suitable with more reactive silicon sources such as disilane.

The primary binding reagent can be bound to the insoluble
20 support by adsorption, ionic bonding, van der Waals adsorption, electrostatic bonding, or other non-covalent bonding, or it can be bound to the insoluble support by covalent bonding. Procedures for non-covalent bonding are described in U.S. Patent No. 4,528,267. Procedures for covalently bonding antibodies and antigens to
25 insoluble supports are described by Ichiro Chibata in IMMOBILIZED ENZYMES. Halsted Press: New York (1978) and A. Cuatrecasas, *J. Bio. Chem.* 245:3059 (1970).

The surface can be coated with a protein and coupled with the primary binding reagent using
30 procedures described in U.S. Patent 4,210,418 using glutaraldehyde as a coupling agent, for example. In another procedure, the insoluble support can be coated with a layer having free isocyanate groups such as a polyether isocyanate, and application of the

1305921

-19-

antibody or antigen in aqueous solution thereto effects the requisite bonding. In further procedure, the antibody or antigen can be coupled to a hydroxylated material by means of cyanogen bromide as described in U.S. Patent 3,720,760.

5 Fig. 6 is a schematic representation of a process for preparing the insoluble support with a diffraction grating design of primary binding reagent shown in Fig. 5. Any smooth surface having the requisite high binding affinity for primary binding reagent can be used in this process. For purposes of clear explanation and not by
10 way of limitation, the process is described for a semiconductor wafer with a polished surface bearing a polysilicon coating. It should be understood that the same, equivalent, or similar procedures can be applied for preparing diffraction gratings designs with primary binding reagents with other high binding
15 smooth surfaces.

 With the preferred insoluble supports of aluminum, silicon nitride, silicon dioxide, single crystalline silicon, and particular the polysilicon surfaces, the primary binding reagent can be applied by simple adsorption. In one procedure for
20 non-covalent adhesion of primary binding reagent to the surface of an insoluble support, a primary binding reagent such as an antibody, antigen, hapten-protein conjugate, lectin, enzyme substrate, protein A, enzyme inhibitor or protein receptor is applied to the surface of a support such as a polysilicon surface
25 150 in an aqueous buffer solution 152. The buffered primary binding reagent solution is placed in a container with the support bearing the polysilicon surface and incubated at room temperature until adsorption occurs, for example for from 0.5 to 18 hours and preferable from 1 to 3 hours, at temperatures of from 4 to 40 C and
30 preferable from 20 to 26 C. The polysilicon surface is then rinsed with a buffered saline solution and dried.

 The concentration of primary binding reagent in the buffer solution is selected to provide the desired reagent density on the

1305921

-20-

polysilicon surface. The primary binding reagent solution can contain from 0.02 to 100 micrograms/ml of the primary binding reagent and preferably contains from 10 to 50 micrograms/ml of the primary binding reagent in a buffered solution having a pH of from
5 6.0 to 9.5 and preferably from 7.0 to 8.5.

Binding reagents are chosen to bind selectively with the analyte to be measured in a sample. For example, the binding reagent can be a polyclonal antibody, a monoclonal antibody or a mixture of monoclonal antibodies binding specifically with a sample
10 analyte to be measured. Alternatively the binding pair can comprise an antibody Fa, Fb, Fab, F(ab')₂ fragment or hybrid antibody. For determining antibodies binding with a specific antigen in a sample, the binding reagent can be an antigen binding with the analyte antibody, such as an allergen which binds with IgE
15 antibody in a solution. The binding reagent can also be a hapten or antigen conjugated with a water-soluble protein or polymer which adheres more strongly or more uniformly to the polysilicon surface than the simple hapten or antigen. The binding reagent can be other binding reagents such as a member of a hapten-antibody
20 binding pair, an enzyme-enzyme substrate binding pair, a lectin-sugar binding pair, an avidin-biotin binding pair, an IgG antibody Fc portion-Protein A binding pair; enzyme-enzyme inhibitor binding pair; protein-protein receptor binding pair; chelating agent-ligand binding pair; and the like. Also included are members
25 of specific binding pairs wherein a mercapto group binds specifically with a dithio or disulfide group (-SH - -S-S-) or with a N-substituted-2,4-diketo-3-pyrroline group, and other molecules with functional groups that will bind each other specifically. In general, the binding reagent is selected to bind specifically or
30 selectively with the analyte, the material for which a sample is assayed.

The surface 150 with the coating 156 thereon is then rinsed and dried.

1305921

-21-

A suitable rinse solution is an aqueous phosphate buffer solution such as is described in U.S. Patent No. 4,528,267 having a phosphate molarity of from 0.0001 to 0.05, a pH of from 6 to 8 and containing from 0.001 to 0.1 weight percent non-ionic surfactant and from 0.0001 to 0.5 weight percent of an animal serum albumin. Suitable non-ionic surfactants include polyoxyethylene ethers (BRIJ) such as lauryl, cetyl, oleyl, stearyl, and tridecyl polyoxyethylene ethers; polyoxyethylenesorbitans (TWEEN) such as polyoxyethylenesorbitan monolaurate, monopalmitate, monostearate, monoleate and trioleates; and other polyoxyethylene ethers (TRITON), for example. Preferred non-ionic surfactant are the polyoxyethylenesorbitans such as polyoxyethylenesorbitan monolaurate (TWEEN 20)*.

A mask is prepared by photographic methods conventional in semiconductor manufacturing. For example, a mask having a plurality of diffraction gratings having the desired line density and line widths can be prepared on a quartz glass or other UV-transparent plate through a photoresist process similar to photography. The dark lines of the mask correspond to active primary binding reagent areas desired on the ultimate surface.

In Step C, the shadow mask 158 is positioned in at a preselected distance from surface 150 to project a precise shadow of lines on the surface 150 having a coating 156 of primary binding reagent thereon using conventional projection alignment techniques. The mercury-xenon illuminator 161 projects an intense, uniform collimated beam of UV light onto a photomask 158. The photomask 158 is mechanically held by a mask holder 159 at the desired distance from the surface 156 to produce non-contact projection of precision images onto the coated surface. The proximity gap 162 can range from 5 to 20 microns from the coated surface 150.

*Trade-mark

1305921

-22-

The projection alignment equipment and the projection methods involved in the operation thereof are well known in the art and do not form a part of this invention. The ORIEL[®] photolithography illuminator and the accessories therefor (Oriel Corporation, 5 Stratford, CT.) is suitable for this purpose.

In this method, contact of the coating 156 with the mask 158 is entirely avoided, a critical feature which provides the superior diffraction grid of this invention. The surface is exposed to the precisely focused ultraviolet radiation until the binding 10 capability of the portions of the primary binding reagent exposed to the radiation are substantially reduced or preferably eliminated. To manufacture a precision grating design, the radiation should form a sharp image on the coated surface.

The ultraviolet radiation exposure required to deactivate 15 coating exposed thereto depends upon the primary binding reagent. For antibody primary binding reagents, exposure times of from 30 sec to 30 min and preferably from 1 to 5 min is sufficient with a ultraviolet radiation having a wavelength such as 254 nm and a power of from 8 to 14 milliwatts per cm². Some adjustment in 20 time of exposure and/or power may be necessary to deactivate the binding sites of other antibody binding agents.

To alter the epitopes of antigenic primary binding reagents such as human IgG, exposure times of from 30 to 120 min and preferably from 45 to 60 min are sufficient with a ultraviolet 25 radiation having a wavelength of 254 nm and a power of from 8 to 14 milliwatts per cm². Some adjustment in time of exposure and/or power may be necessary to alter or destroy the binding sites of other binding agents.

This treatment reduces or eliminates the binding properties of 30 the primary binding reagent in lines 146, leaving active primary binding reagent in a diffraction grating design as the lines 144 of Fig. 5.

1305921

-23-

The coated substrate containing areas having binding protein in a diffraction grating design is then cut into smaller area chips 160, each chip having a size sufficient to perform an immunoassay. These chips are then mounted on a suitable diagnostic support such as the dipstick shown in Fig. 4.

The improved biogrid products of this invention provided improved sensitivity in immunoassay methods using light diffraction. One such method comprises a first step of contacting the insoluble support with the biological diffraction grating design or pattern of binding agent thereon with the sample to be assayed for an analyte which binds specifically with the binding agent. The insoluble support is contacted with the sample for a time sufficient to permit conjugation of the binding agent and the analyte. The sample is then removed from the insoluble support, preferably with a suitable buffered rinse solution such as described hereinabove. This procedure leaves the diffraction grating design of binding agent coupled with the analyte.

Light disturbing gratings are directly formed with most analytes. The conjugation of the binding agent and the analyte converts the binding agent design into a diffraction grating. The microbe or fragment of a bacteria, virus, Mycoplasmatales, spore, parasite and yeast, an enzyme or other organic substance, an antigenic protein such as an immunoglobulin, or an organic compound and substances having a lower molecular weight adheres to the insoluble support in a diffraction grating pattern, and light illuminating the surface is diffracted.

If the binding agent-analyte conjugation product is non-light disturbing, the second step comprises conjugating the insoluble support with a secondary binding reagent which is labeled with one or more light disturbing substances which affect light by absorption, reflection, scattering, refraction or phase changing. Specific examples include chromophores and other light absorbing materials, and reflective and light transmitting beads and other

1305921

-24-

light reflecting and scattering materials. Alternatively it can be coupled with a secondary binding reagent which can be specifically conjugated with a binding partner therefor which is labeled with a chromophore or light absorbing material. This alternative coupling
5 can occur during or subsequent to the secondary binding reagent treatment in the second step.

The choice of secondary binding reagent is made depending upon the type of analyte being assayed. If the analyte is an IgG antibody, for example, the secondary binding reagent can be either
10 an IgG specifically binding antibody or Protein A, suitably labeled with a light disturbing material. In general, the secondary binding reagent is an antibody of a selected class which binds specifically with the analyte, usually an IgG class antibody.

Suitable chromophore labels are any light absorbing pigment or
15 dye which absorbs light of the wavelength produced by the light source. Coupling of the binding reagent-analyte conjugation product with such a chromophore converts the light diffracting design into a diffraction grating. Alternatively, the light absorbing label can be another type of light disturbing particle or
20 reflective material such as colloidal gold or silver, or latex microspheres.

In the alternative method which has increased sensitivity using the improved biogrids of this invention, the secondary binding partner label is selected to bind specifically with a tertiary
25 binding reagent which is labeled with a suitable light disturbing material. Examples of binding pairs for which either partner can be used as the secondary binding partner label are avidin-biotin, IgG antibody-Protein A, hapten-antihapten antibody, and the like. If the secondary binding reagent is an IgG antibody, for example,
30 it can be unlabeled, since the Fc chain portion thereof is a binding partner for Protein A or anti-IgG antibodies.

Following conversion of the biological diffraction design to a diffraction grating, insoluble support is rinsed with distilled or

1305921

-25-

deionized water. Then the strength of the light diffraction is measured with a suitable light diffraction instrument such as is illustrated in Fig. 1. The relative strengths of the light diffracted is a function of the amount of primary binding reagent-analyte conjugate comprising the grating. By repeating the above procedure with a prepared series of solutions containing a range of different known concentrations of analyte therein, a standard curve functionally related to the strength of the diffracted light is obtained. By comparing the reading obtained with the sample containing the analyte with the curve obtained with solutions containing known concentrations of the analyte, the concentration of analyte in the sample can be determined. Comparing the strengths of the first, second, third, etc. order diffractions with each other and with the strength of the reflected light directly provides an indication of the degree of conjugation with the grating binding agent.

In a competition immunoassay alternative method using the improved biogrids of this invention, the insoluble support with the biological diffraction grating design of binding agent thereon can be contacted with a mixture of the analyte sample and a reagent analyte labeled with a label which is light disturbing. The amount of reagent analyte binding with the primary binding agent will be an inverse function of the amount of analyte in the sample. The density of the diffraction grating formed will therefor have a functional relationship with the concentration of analyte in the sample, and this difference can be detected in the strength of diffracted light.

This invention is further illustrated by the following specific but non-limiting examples. Unless otherwise specified, percents are provided as weight percents and temperature as degrees Centigrade. Examples which have been carried out in the laboratory are set forth in the past tense, and examples setting forth procedures which are constructively reduced to practice herein are set forth in the present tense.

1305921

-26-

EXAMPLE 1

Antibody Diffraction Grating Pattern

A polysilicon coated silicon wafer is immersed in a solution of a goat anti-(human IgG) antibody primary binding reagent of class
5 IgG diluted in 0.1 M phosphate buffered solution, pH 7.4, with 0.1 wt.% sodium azide preservative for 1 hr. The wafer is then removed from the antibody solution, rinsed with buffered saline, and dried.

A mask having a series of squares corresponding in size and shape to the ultimate chip product and with diffraction grating
10 lines having a line spacing of 10 micrometers, a line width of 5 micrometers and a line density of 1000 lines/cm is positioned in an alignment projector and a sharp image of the lines on the mask is projected with ultraviolet light having a wavelength of 254 nm and a strength of 9.6 milliwatts per cm² for 3 min.

15 The wafer is then immersed in a 0.1 M phosphate buffer solution (PBS), pH 7.4, containing 2.5 wt.% sucrose, 0.25 wt.% bovine serum albumin (BSA), and 0.1 wt.% sodium azide for 30 min, the excess is removed, and the wafer dried.

The wafer is then cut into square chips having a diffraction
20 grating pattern of anti-IgE antibody thereon, and mounted in a receptive cavity on the surface of a dipstick.

EXAMPLE 2

Antigen Diffraction Grating Pattern

25 Repeating the procedure of Example 1, but replacing the anti-(human IgG) antibody with a ragweed pollen allergen, and exposing the mask to the ultraviolet light having a wavelength of 254 nm for 60 min yields a dipstick with chips on the surface thereof having a diffraction grating pattern of allergen thereon.

30

EXAMPLE 3

Serum IgG Immunoassay

The dipstick product of Example 1 is immersed in patient serum

1305921

-27-

and incubated for 1 hr. The serum is removed, and the chip is rinsed three times with a buffered rinse solution containing 0.85 wt.% sodium chloride, 0.05 wt.% TWEEN 20 and 0.1 wt.% sodium azide preservative in a 0.01 M aqueous phosphate buffer solution, pH 7.4. The diffraction grating pattern of anti-IgG antibody is conjugated with serum IgG.

The dipstick is then incubated 30 min with 100 microliters of a solution of goat anti-IgG antibody immobilized on 20 nm colloidal gold particles (E. Y. Laboratory, San Mateo, CA). The antibody is applied in a solution of 0.002 M borate buffer, pH 8.5. The chip is rinsed thoroughly with distilled water.

The intensity of the light diffracted by the grating is then measured using polarized monochromatic light having a wavelength of 632.8 nm from a helium-neon laser.

The procedure is repeated with dilutions of human serum containing a known amount of IgG antibodies to establish a reference curve with which the intensity of the diffracted light obtained with the patient serum sample is compared.

EXAMPLE 4

Ragweed Specific IgE Immunoassay

A dipstick product of Example 2 having a diffraction grating pattern of ragweed pollen allergen thereon is contacted with patient serum to be assayed for ragweed pollen allergen binding IgE and incubated for 2 hrs. The serum is removed, and the chip is rinsed three times with a buffered rinse solution containing 0.85 wt.% sodium chloride, 0.05 wt.% TWEEN 20 and 0.1 wt.% sodium azide preservative in a 0.01 M aqueous phosphate buffer solution, pH 7.4. The diffraction grating pattern of ragweed pollen allergen is conjugated with serum IgE antibody.

The chip is then contacted for 30 min with 100 microliters of a solution of gold colloid particle labeled goat anti-IgE antibody (E.Y. Laboratories, San Mateo, CA). The chip is rinsed thoroughly with distilled water.

1305921

-28-

The intensity of the light diffracted by the grating is then measured using polarized monochromatic light having a wavelength of 632.8 nm from a helium-neon laser.

The procedure is repeated with dilutions of human serum
5 containing a known amount of ragweed pollen allergen specifically binding IgE antibodies to establish a reference curve with which the intensity of the diffracted light obtained with the patient serum sample is compared.

10

EXAMPLE 5

Serum IgG Immunoassay

The dipstick having a diffraction grating pattern of anti-(human IgG) antibody thereon prepared in accordance with the procedure of Example 2 is contacted with a mixture of 100
15 Microliters of patient serum and 100 microliters of a solution of gold colloid particle labeled goat anti-IgG antibody described in Example 3 and incubated for 1 hr. The chip is rinsed thoroughly with distilled water. The diffraction grating pattern of anti-IgG antibody is conjugated with serum IgG antibody conjugated with gold
20 labeled anti-IgG antibody.

The intensity of the light diffracted by the grating is then measured using polarized monochromatic light having a wavelength of 632.8 nm from a helium-neon laser.

The procedure is repeated with dilutions of human serum
25 containing a known amount of serum IgG antibodies to establish a reference curve with which the intensity of the diffracted light obtained with the patient serum sample is compared.

EXAMPLE 6

30

Anti-viral Antibody

Diffraction Grating Pattern

A polysilicon coated silicon wafer is immersed in a solution of a rabbit anti-(hepatitis A) antibody (U.S. Patent 4,596,674)

1305921

-29-

diluted in 0.1 M phosphate buffered solution, pH 7.5, with 0.1 wt.% sodium azide preservative for 2 hrs or overnight. The wafer is then removed from the antibody solution, rinsed with buffered saline, and dried.

5 A mask having a series of squares corresponding in size and shape to the ultimate chip product and with diffraction grating lines having a line spacing of 10 micrometers, a line width of 5 micrometers and a line density of 1000 lines/cm is positioned in an alignment projector focused to project a sharp image of the lines
10 on the mask on the antibody surface. The surface is exposed to focused ultraviolet light having a wavelength of 254 nm and a strength of 9.6 milliwatts per cm^2 for 3 min.

15 The wafer is then immersed in a 0.1 M phosphate buffer solution (PBS), pH 7.4, containing 2.5 wt.% sucrose, 0.25 wt.% bovine serum albumin (BSA) and 0.1 wt.% sodium azide for 30 min, the excess is removed, and the wafer dried.

20 The wafer is then cut into square chips having a diffraction grating pattern of anti-(hepatitis A) antibody thereon, and mounted on the surface of a polyethylene dipstick.

EXAMPLE 7

Anti-(Streptococcus A) Antibody

Diffraction Grating Pattern

25 Repeating the procedure of Example 6, but replacing the anti-(hepatitis A) antibody with anti-(Streptococcus A) antibody, and exposing the mask to the ultraviolet light having a wavelength of 254 nm and a strength of 9.6 milliwatts per cm^2 for 3 min yields a dipstick plate with a chip on the surface thereof having a diffraction grating pattern of anti-(Streptococcus A) antibody
30 thereon.

1305921

-30-

EXAMPLE 8

***Anti-(Mycoplasmatales pneumoniae) Antibody
Diffraction Grating Pattern***

Repeating the procedure of Example 6, but replacing the
5 anti-(hepatitis A) antibody with anti-(M. pneumoniae) antibody, and
exposing the mask to the ultraviolet light having a wavelength of
254 nm and a strength of 9.6 milliwatts per cm² for 3 min yields
a dipstick having a chip on the surface thereof having a
diffraction grating pattern of anti-(M. pneumoniae) antibody
10 thereon.

EXAMPLE 9

Anti-HCG Antibody

Diffraction Grating Pattern

15 Repeating the procedure of Example 6, but replacing the
anti-(hepatitis A) antibody with anti-(human chorionic gonadotropin
(HCG)) antibody, and exposing the mask to the ultraviolet light
having a wavelength of 254 nm and a strength of 9.6 milliwatts per
cm² for 3 min yields a dipstick having a chip on the surface
20 thereof having a diffraction grating pattern of anti-(human
chorionic gonadotropin) antibody thereon.

EXAMPLE 10

Hepatitis A binding assay

25 Patient serum is added to the surface of a polysilicon chip
product of Example 6 and incubated for one hr. The serum is
removed, and the chip is rinsed thoroughly with distilled water,
and excess water is removed. The diffraction grating pattern of
anti-(hepatitis A) antibody is conjugated with hepatitis A virus in
30 the serum.

The intensity of the light diffracted by the grating is then
measured using monochromatic light having a wavelength of 632.8 nm
from a helium-neon laser.

1305921

-31-

The procedure is repeated with a positive control containing a known amount of hepatitis A virus to establish a reference point cut off with which the intensity of the diffracted light obtained with the patient serum sample is compared.

5

EXAMPLE 11

Streptococcus A binding assay

A polysilicon chip product of Example 7 having a diffraction grating pattern of anti-(Streptococcus A) antibody thereon is contacted with patient throat swab extract to be assayed for Streptococcus infection and incubated for 15 min. The sample is removed, and polysilicon surface is rinsed thoroughly with distilled water, and the excess water is removed. The diffraction grating pattern of anti-(Streptococcus A) antibody is conjugated with Streptococcus A in the patient sample.

10

15

The procedure is repeated with a positive control containing a known amount of Streptococcus A to establish a reference point cut-off with which the intensity of the diffracted light obtained with the patient sample is compared.

20

EXAMPLE 12

Mycoplasma pneumoniae binding assay

A polysilicon chip product of Example 8 having a diffraction grating pattern of anti-(M. pneumoniae) antibody thereon is contacted with patient expectorate to be assayed for M. pneumoniae infection and incubated for 0.5 hrs. The sample is removed from the chip, the chip is thoroughly rinsed with distilled water, and the excess water is removed. The diffraction grating pattern of anti-(M. pneumoniae) antibody is conjugated with M. pneumoniae in the sputum.

25

30

The procedure is repeated with a positive control containing a known amount of M. pneumoniae to establish a reference point

1305921

-32-

cut-off with which the intensity of the diffracted light obtained with the patient serum sample is compared.

EXAMPLE 13

5 HCG binding assay

 A polysilicon chip product of Example 9 having a diffraction grating pattern of anti-(human chorionic gonadotropin) antibody thereon is contacted with patient serum to be assayed for the presence and level of HCG and incubated for 0.5 hrs. The sample is
10 removed from the chip, the chip is thoroughly rinsed with distilled water, and the excess water is removed. The diffraction grating pattern of anti-(human chorionic gonadotropin) antibody is conjugated with HCG present in the serum.

 The procedure is repeated with a positive control containing a
15 known amount of HCG to establish a reference point cut-off with which the intensity of the diffracted light obtained with the patient serum sample is compared.

1305921

-33-

WE CLAIM:

1. A biograting for use in a light diffraction immunoassay comprising a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent.
2. The diffraction immunoassay plate of Claim 1 wherein the binding reagent is selected from the group consisting of antibody, antigen, hapten, protein A, lectin, biotin and avidin.
3. The diffraction immunoassay plate of Claim 1 wherein the biological diffraction grating design of lines of active binding reagent is non-light disturbing.
4. The diffraction immunoassay plate of Claim 1 wherein the insoluble surface is polysilicon.
5. In the process for manufacturing the biograting of Claims 1, 2, 3 or 4 comprising adhering a uniform layer of binding reagent on a smooth, solid surface and exposing the surface to UV radiation through a shadow mask with diffraction grating lines to selectively deactivate the binding reagent leaving a biological diffraction grating design of lines of active binding reagent, the improvement comprising applying the binding reagent to a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent.
6. The process of Claim 5 wherein the improvement comprises casting a precise focused shadow on the binding reagent layer without physically contacting the binding reagent layer with the shadow mask.

1305921

-34-

7. In a process for manufacturing a biograting for use in a light diffraction immunoassay comprising adhering a uniform layer of binding reagent on a smooth, solid surface and exposing the surface to UV radiation through a shadow mask with diffraction grating lines to selectively deactivate the binding reagent to leave a biological diffraction grating design of lines of active binding reagent, the improvement comprising casting a precise focused shadow on the binding reagent layer without physically contacting the binding reagent layer with the shadow mask.
8. The process of Claim 7 wherein the binding reagent is selected from the group consisting of antibody, antigen, hapten, protein A, lectin, biotin and avidin.
9. The process of Claim 7 wherein the improvement comprises applying the binding reagent to a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent.
10. The process of Claim 9 wherein the insoluble surface is polysilicon.
11. A biograting for use in a light diffraction immunoassay comprising a surface selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a biological diffraction grating design of lines of active binding reagent which is the product of the process of Claims, 7, 8, 9 or 10.

1305921

-35-

12. A diffraction binding assay method for determining the presence or quantity of an analyte in an aqueous sample comprising
- a) contacting a diffraction binding assay surface with the sample for a time sufficient to permit conjugation of binding reagent and analyte, the diffraction binding assay surface being selected from the group consisting of polysilicon and single crystalline silicon surfaces having on said surface, a light disturbing design of substantially non-light disturbing binding reagent thereon, the binding reagent being selected to bind selectively with the analyte;
 - b) separating the surface from the sample; and
 - c) illuminating the diffraction binding assay surface with light from a light source, and determining the light diffracted by the diffraction binding assay surface.
13. The diffraction binding assay method of Claim 12 wherein the analyte is a microbe or fragment thereof.
14. The diffraction binding assay method of Claim 13 wherein the analyte is a bacteria, virus, Mycoplasma, spore, parasite, yeast, or fragment thereof.
15. The diffraction binding assay method of Claim 13 wherein the analyte is an organic substance having a molecular weight within the range of from 10,000 to 2,000,000 daltons.
16. The diffraction binding assay method of Claim 15 wherein the analyte is an organic substance having a molecular weight of 30,000 daltons or higher.
17. The diffraction binding assay method of Claim 13 wherein the analyte is an enzyme, enzyme inhibitor, enzyme substrate, immunoglobulin, hormone, drug, drug metabolite, sequence, receptor, tumor associated marker, or carbohydrate.
18. The diffraction binding assay method of Claim 14 wherein the insoluble surface is polysilicon.

1305921

-36-


19. The diffraction binding assay method of Claim 18 wherein the smooth insoluble surface has been treated with an aqueous solution of a non-specific binding inhibitor.
20. The diffraction binding assay method of Claim 19 wherein the
5 non-specific binding inhibitor is a water-soluble protein or polyamino acid.



2025-11-21 15:22:22

1305921

3-1






FIG. 2.




FIG. 3.

